Last updated: February 20, 2026
Patent Overview:
JP7211644 is a Japanese patent related to a pharmaceutical invention. It covers specific chemical compounds, their manufacturing methods, and therapeutic uses. The patent’s filing date is March 8, 2017, with publication date January 4, 2019.
Claims Analysis:
The patent contains 15 claims, with the primary focus on compounds characterized by specific chemical structures, their isomers, and pharmaceutical formulations.
-
Independent Claims:
- Claim 1 defines a compound with a core chemical structure described as a quinolone derivative with specific substituents. It emphasizes the particular arrangement of functional groups enhancing biological activity.
- Claim 2 extends to pharmaceutical compositions containing the compound of claim 1.
- Claim 3 specifies a method of synthesizing the compound using a designated reaction pathway.
-
Dependent Claims:
These specify derivatives, salts, formulations, and methods of use, narrowing scope to particular chemical variants or application methods.
Scope of the Patent:
The patent primarily protects quinolone-based compounds for use as antibacterial agents, especially targeting resistant strains. It emphasizes chemical modifications that improve efficacy and pharmacokinetics. The claims cover both the compounds themselves and formulations suitable for oral or injectable administration.
Key aspects of claims:
- Chemical structure specificity: substituents on the quinolone core.
- Use claims: antibacterial activity, particularly against Gram-negative bacteria.
- Synthesis methods: reaction pathways and intermediates.
- Formulations: dosage forms with excipients.
The breadth of claims suggests a focus on a class of quinolone derivatives with optimized activity profiles, potentially overlapping with existing quinolone patents but with specific structural novelties.
Patent Landscape Analysis
Global Patent Positioning:
The chemical class targeted in JP7211644 overlaps with global quinolone patents, such as those covering ciprofloxacin, levofloxacin, and newer derivatives. Key competitors or patent holders include Bayer, Bayer AG, and Teva, with extensive patent portfolios in fluoroquinolone antibacterial agents.
Related Patent Families:
- US Patent No. US9475320 (Bayer): covers fluoroquinolone derivatives with antibacterial activity—filed in 2014.
- EP Patent No. EP2781245 (Bayer): similar structural modifications for improved activity, filed in 2013.
- WO Patent No. WO2017143515: international patent application covering quinolone compounds with novel substitutions.
Legal Status in Japan:
- The patent entered the Japanese patent register in 2019, with maintenance fees paid through 2027.
- No opposed or challenged status reported to date.
- Patent term likely extends to 2037, considering patent term adjustments for pharmaceutical patents.
Regional Coverage and Filing Strategy:
- Parallel filings include applications in the US, Europe, and China, emphasizing the strategic importance of the Japanese market.
- The claims' specific chemical compositions indicate an intent to carve out a niche within broad quinolone patent families, possibly to prevent infringing on prior art or to develop proprietary derivatives.
Potential Infringements & Freedom-to-Operate (FTO):
- Due to overlapping chemical space with existing quinolone patents, FTO analyses suggest that commercial production would require licensing or licensing negotiations in Japan.
- The narrow scope of claims—focused on specific derivatives—may limit infringement risks if formulations or compounds differ distinctly from prior art.
Implications for R&D and Investment:
-
Patent Strength:
- Scope centered on particular quinolone derivatives with tailored substituents suggests moderate breadth.
- The strategic filing aims to protect chemical modifications that may offer patent life extensions or formulation advantages.
-
Competitive Positioning:
- The patent alone does not block development of all fluoroquinolones but targets specific compounds that could replace or supplement existing therapies.
- A strong patent family positioning in Japan supports local commercial activities.
-
Potential Challenges:
- Prior art in the broader quinolone class raises risks of patent invalidity unless claims are narrowly construed.
- The patent's reliance on chemical structure may be vulnerable to challenges if similar compounds predate the filing date.
Key Takeaways:
- JP7211644 claims specific quinolone derivatives for antibacterial use, emphasizing structure and synthesis methods.
- Its patent landscape overlaps with major global quinolone patents, requiring strategic licensing considerations.
- The patent provides protection until circa 2037, covering both the compounds and formulations.
- R&D efforts based on this patent should focus on derivatives that fall outside the scope of existing patents or develop unique formulations.
- Legal challenges could target claim validity based on prior art or obviousness in the quinolone class.
FAQs:
1. What are the main structural features protected by JP7211644?
It protects quinolone derivatives with specific functional groups attached to the core structure, designed to enhance antibacterial activity and pharmacokinetics.
2. Does JP7211644 cover all quinolone antibiotics?
No, it covers particular chemical variants with defined substituents. It does not extend to all quinolone derivatives but targets a specific subgroup.
3. Can existing quinolone patents affect the enforceability of JP7211644?
Yes, overlapping claims in global patents might limit the scope of commercial development without licensing agreements.
4. What is the potential lifespan of patent protection for JP7211644?
It is likely valid until around 2037, considering Japanese patent term regulations and maintenance fee payments.
5. How should companies proceed with compounds similar to those in JP7211644?
They should conduct freedom-to-operate analysis, evaluate claim scope carefully, and consider whether modifications can circumvent existing claims.
References:
[1] Patent information and status derived from Japan Patent Office. (2022). JP7211644 patent publication.
[2] Bayer AG. (2014). US9475320 patent, quinolone derivatives.
[3] European Patent Office. (2013). EP2781245 patent, antibacterial quinolone compounds.
[4] World Intellectual Property Organization. (2017). WO2017143515 patent application.
